Migdal Insurance & Financial Holdings Ltd. Argenx Se Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.18 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 02, 2022	SELL	$254.45 - $351.06 $7,124 - $9,829	-28 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$272.01 - $353.03 $27,745 - $36,009	-102 Reduced 78.46%	28 $10,000
Q3 2021 Nov 16, 2021	BUY	$295.0 - $350.58 $38,350 - $45,575	130 New	130 $39,000

Others Institutions Holding ARGX

# of Institutions

400

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

Price T Rowe Associates Inc Baltimore, MD

5.82M
Shares

$3.28 Billion
0.36% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

3.51M
Shares

$1.98 Billion
2.99% of portfolio
Janus Henderson Group PLC London, X0

2.48M
Shares

$1.4 Billion
0.72% of portfolio
Capital World Investors Los Angeles, CA

1.7M
Shares

$959 Million
0.15% of portfolio
Avoro Capital Advisors LLC New York, NY

1.24M
Shares

$699 Million
10.11% of portfolio

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account